PCI further facilitated antigen presentation by causing up-regulation of MHC and co-stimulatory proteins on the surface of APCs as well as their production of TNF-α and IL-1β in vivo. Furthermore, PCI-based vaccination also caused local inflammation at the site of vaccination, showing strong infiltration of immune cells, which could contribute to the stimulation of antigen-specific immune responses. This study is the first to demonstrate that a live microbial vaccine can be combined with a photochemical compound and light for cross presentation of antigens to CD8 T cells. Moreover, the results revealed that PCI treatment strongly improved the immunogenicity of M. bovis BCG.
Oslo (Norway), 11 January 2022 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, todayannounced that results from preclinical studies on tuberculosisperformed in collaboration with The University of Zurich and ETH Zurich are
Oslo (Norway), 11 January 2022 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, todayannounced that results from preclinical studies on tuberculosisperformed in collaboration with The University of Zurich and ETH Zurich are accepted for publication in Frontiers in Immunology, a high impact immunology journal. The article title is "Photochemically-mediated inflammation and cross-presentation of Mycobacterium bovis BCG proteins stimulates strong CD4 and CD8 T-cell responses in mice” and the abstract of the publication is available through this link:www.frontiersin.org/articles/10.3389/fimmu.2022.815609/abstract.
Anders Høgset, CSO of PCI Biotech, comments: “Infectious diseases are not within PCI Biotech’s core focus areas, but these positive results support our general understanding of fima Vacc ’s mode of action and further demonstrate the broad potential of the technology.”
Dette var SOLID 
Det nye teknologiben vil kanskje bli kalt fimaBacc!
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019092215&_cid=P20-K4D5L6-32545-1
Denne teknologien vil kanskje bidra til forskning og utvikieng ved en Av DE STØRSTE utfordringer for menneskeheten (WHO)? Antibiotika resistente bakterier!
Nevnt på PCI tråder tidligere. Men blir bare mer interessant med disse resultater meldt i dag i Journal Frontier
17-åring reddet av ny behandling. Kan erstatte antibiotika.
Antibiotikaresistente bakterier er på fremmarsj. Nå kan et virus være løsningen på helseproblemet som skremmer mange.
Resistens behandlet med virus. Blir interessant å høre om muligheter og konkurransesituasjonen etterhvert.
Ser ut som Nordnet har lettet seg siste tid, eller som tidligere beskrevet på PCI tråd, lånt ut til short? Det var en skribent som viste til da at PCI var en av de med størst inntekter et kvartal / måneder til utlån. Er det slik igjen eller bare ordinært salg som er gjort?
Anyway, nu er det kun gledelig å se teknologiplattformen bli større med flere gode resultater å vise til. Ikke minst et ENORMT behov for løsning, fimaBACC kan være en teknologi. Det brukes enorme ressurser på et av de største utfordringer for menneskets helse og framtid.
WHO
Antibiotic resistance is rising to dangerously high levels in all parts of the world. New resistance mechanisms are emerging and spreading globally, threatening our ability to treat common infectious diseases. A growing list of infections – such as pneumonia, tuberculosis, blood poisoning, gonorrhoea, and foodborne diseases – are becoming harder, and sometimes impossible, to treat as antibiotics become less effective.
Where antibiotics can be bought for human or animal use without a prescription, the emergence and spread of resistance is made worse. Similarly, in countries without standard treatment guidelines, antibiotics are often over-prescribed by health workers and veterinarians and over-used by the public.
Without urgent action, we are heading for a post-antibiotic era, in which common infections and minor injuries can once again kill.
